Register to receive Actonel updates

Please complete the fields below (*denotes a required field).

*First Name: ↑ Please enter your first name Minimum number of characters not met.Exceeded maximum number of characters.
*Last Name: ↑ Please enter your last name
*Specialty: ↑ Please select your specialty
Phone:
Mobile Phone:
(for text message updates)
Fax:

*Email: ↑ Please enter your email address ↑ Invalid format
*Address 1: ↑ Please enter your address
Address 2:
*City: ↑ Please enter your city
*State: ↑ Please select your state
*ZIP Code: - ↑ Please enter your ZIP code ↑ Invalid format
*Birthdate Month Day Year

Trust is a cornerstone of our corporate mission, and the success of our business depends on it. P&G is committed to maintaining your trust by protecting personal information we collect about you, our consumers. Click here for the full details of our Privacy Statement.

By providing your email address you agree to receive additional information via email (or text message if a mobile phone number is provided) from P&G Pharmaceuticals. Your name, address, and any other personal information provided will be available only to P&G and companies working for P&G, who will use it to deliver the service(s) requested. The companies working for P&G have agreed only to use this information at the direction of P&G and have also agreed not to share this information with anyone else. P&G will not disclose personal information about you to anyone other than these companies, except as required by law.

Actonel is indicated for the treatment of postmenopausal osteoporosis.
Actonel 5 mg and 35 mg are indicated for the prevention of postmenopausal osteoporosis.
Actonel 150 mg may be considered for use for prevention of postmenopausal osteoporosis.

Selected Safety Information for Actonel

Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least
30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

Bisphosphonates, including Actonel, may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcers. Actonel should be taken according to the dosing instructions to minimize the risk of these events. Patients should discontinue use if new or worsening symptoms occur. There have also been reports of severe and occasionally incapacitating bone, joint and/or muscle pain in patients taking bisphosphonates.

Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Actonel. Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan (including the consideration of discontinuation of bisphosphonate therapy) of each patient based on individual benefit/risk assessment.

Most common adverse reactions reported in >10% of patients treated with Actonel and with a higher frequency than placebo are: back pain, arthralgia, abdominal pain, and dyspepsia. Hypersensitivity reactions (angioedema, generalized rash, bullous skin reactions), and eye inflammation (iritis, uveitis) have been reported rarely.

Please click for Full Prescribing Information for Actonel.

This material is provided in Adobe Acrobat PDF format. If you don't have Acrobat Reader, you can download it by clicking below.